Compare ONFO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONFO | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Israel |
| Employees | 27 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.8M |
| IPO Year | N/A | 2012 |
| Metric | ONFO | RDHL |
|---|---|---|
| Price | $1.64 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 48.1K | 19.3K |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.71 |
| 52 Week High | $1.95 | $3.31 |
| Indicator | ONFO | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 86.19 | 41.68 |
| Support Level | $0.99 | $0.80 |
| Resistance Level | $1.95 | $0.90 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 58.47 | 55.93 |
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Pace Generative.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.